Current position:News > News > Insights
GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
吉满生物
2024-11-06

Novo Nordisk is sticking close to home for its latest GLP-1 deal, signing a $285 million partnership with fellow Danish company Ascendis Pharma to work on new therapeutics for metabolic and cardiovascular diseases.

image.png

Ascendis will provide access to its TransCon technology platform in an effort to find GLP-1 candidates with reduced dosing frequency, according to a Monday press release. The $285 million payment includes an upfront fee plus development and regulatory milestone payments for the lead program, plus royalties. The company is also eligible for $77.5 million in milestones plus sales-based royalties for each additional program.

The lead program is a once-monthly GLP-1 receptor agonist that Novo will initially develop in obesity and type 2 diabetes. The pharma has exclusive rights to later expand to other indications.

Ascendis will lead early development of the product candidates, while Novo will be responsible for the costs. Novo will also handle clinical development through commercialization.

Learn more about our GLP-1R/GCGR/GIPR catalog.



Latest news
Insights
2025-11-05
Accelerating Development of FOLR1 Target to Advance Multidimensional Cancer Therapy
Folate receptor alpha (FRα, FOLR1) is rapidly becoming one of the hottest targets in tumor therapy. With multiple antibody–drug conjugates (ADCs) now entering Phase III trials from global leaders like Eli Lilly and AstraZeneca, and emerging players such as Bio Thera and ProTarget Bio joining the race, competition around this target is intensifying.

From Elahere’s FDA approval to a new generation of FRα-directed ADCs, monoclonal antibodies, CAR-T therapies, and vaccines, the field is shifting from concept validation to clinical reality.

Dive into the full analysis to see how FRα is redefining the landscape of epithelial tumor treatment — and why it’s drawing worldwide attention from oncology innovators.
Insights
2025-10-31
PD-1 × IL-2: A Combined Approach to Redefining Tumor Immunotherapy Strategies
While PD-1 inhibitors have transformed cancer treatment, their limits are becoming clear — and a new wave of innovation is rising. Cytokine engineering and PD-1 × IL-2 fusion therapies are redefining how we think about precision immune activation.

As PD-1 inhibitors reach their limits, the next frontier lies in cytokine engineering. Both Roche and Innovent Biologics are pursuing the PD-1 × IL-2v fusion strategy — yet with fundamentally different design philosophies.
Insights
2025-10-23
TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy
The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.
Current position:News > News > Insights
classify
GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
吉满生物
2024-11-06

Novo Nordisk is sticking close to home for its latest GLP-1 deal, signing a $285 million partnership with fellow Danish company Ascendis Pharma to work on new therapeutics for metabolic and cardiovascular diseases.

image.png

Ascendis will provide access to its TransCon technology platform in an effort to find GLP-1 candidates with reduced dosing frequency, according to a Monday press release. The $285 million payment includes an upfront fee plus development and regulatory milestone payments for the lead program, plus royalties. The company is also eligible for $77.5 million in milestones plus sales-based royalties for each additional program.

The lead program is a once-monthly GLP-1 receptor agonist that Novo will initially develop in obesity and type 2 diabetes. The pharma has exclusive rights to later expand to other indications.

Ascendis will lead early development of the product candidates, while Novo will be responsible for the costs. Novo will also handle clinical development through commercialization.

Learn more about our GLP-1R/GCGR/GIPR catalog.



Message consultation
reset
submit
Message
Message consultation
reset
submit